Manufacturers: Novartis AG
Ribociclib is a kinase inhibitor used to treat HR+, HER2- breast cancer, including high-risk early breast cancer in combination with an aromatase inhibitor, as well as advanced or metastatic breast cancer.
Ribociclib is a kinase inhibitor used to treat HR+, HER2- breast cancer, including high-risk early breast cancer in combination with an aromatase inhibitor, as well as advanced or metastatic breast cancer.
Inhibition of cyclin-dependent kinase 4 and 6 (CDK4/6) may provide protection against oncogenic processes in specific tissue types. For example, CDK4 is not required for normal mammary tissue development based on knockout mouse studies, but it is needed for growth of Ras-induced mammary tumors, suggesting a potential therapeutic window for treatment with lower toxicity. Ribociclib was reported to be a most selective CDK4/6 inhibitor and to have dose dependent antitumor activity in a number of preclinical models. It inhibited growth of tumor cells by arresting the cells at the G1 checkpoint, which prevents the tumor cells from proliferating.
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
3 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
